A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy

Cancer

Volumn 78, Issue 1, 1996, Pages 144-151

  Ettinger, David S ^a   Eisenberg, Peter D ^b   Fitts, David ^c   Friedman, Carl ^c   Wilson Lynch, Karen ^c   Yocom, Karen ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Marin Oncology Associates   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d NONE

Author keywords

5 hydroxytryptamine3; antiemetics; moderately emetogenic chemotherapy; oncology; oral granisetron; receptor antagonists

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GRANISETRON; LORAZEPAM; METHOTREXATE; PROCHLORPERAZINE; PROMETHAZINE; THIETHYLPERAZINE MALEATE; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GENDER; GRANULOCYTOPENIA; HEADACHE; HUMAN; LUNG CARCINOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; REMISSION INDUCTION; SEX FACTORS; VOMITING;

EID: 0029890755     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960701)78:1<144::AID-CNCR20>3.0.CO;2-Z     Document Type: Article

References (43)

1. Morran C, Smith DC, Anderson DA, McArdle CS. Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomized trial of antiemetics. Br Med J 1979; 1:1323-4.
2. Jenns K. Importance of nausea. Cancer Nurs 1994;17:488-93.
3. Coates A, Abraham S, Kay SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end - patient perception of side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
4. Gralla RJ, Clark RA, Kris MG, Tyson LB. Methodology in antiemetic trials. Eur J Cancer 1991;27(1 Suppl):5S-8S.
5. Gralla R, Tyson LB, Kris M, Clark RA. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am 1987;71:289-301.
6. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 1991;83:613-20.
7. Chevallier B. On behalf of the Granisetron Study Group. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990;26(1 Suppl):33S-6S.
8. Chevallier B. The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br J Cancer 1993;68:176-80.
9. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer 1990;26(1 Suppl):23S-7S.
10. De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Lane Allman E. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990;113:834-40.
11. Grunberg SM, Stevenson LL, Russell CA, McDermed JE. Dose ranging Phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1989;7:1137-41.
12. Kamanabrou D. Intravenous granisetron - establishing the optimal dose. Eur J Cancer 1992;28A(1 Suppl):6S-11S.
13. 3 (serotonin) receptor antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-21.
14. Navari R, Gandara D, Hesketh P, Hall S, Maillard J, Ritter H, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-8.
15. 3 antagonist, in the prevention of nausea and vomiting induced by high dose cisplatin. J Clin Oncol 1994;12:2204-10.
16. Riviere A. On Behalf of The Granisetron Study Group. Dose finding study of granisetron in patients receiving high-dose cisplatin chemotherapy. Br J Cancer 1994;69:967-71.
17. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
18. Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter, double-blind, randomized, parallel group study. Oncology 1994;5:113-8.
19. Sledge GW Jr., Einhorn L, Nagy C, House K. Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer 1992;70: 2524-8.
20. Soukop M. On Behalf Of The Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 1990;26(1 Suppl):15S-9S.
21. Fraschini G. Antiemetic activity of ondansetron in cancer patients receiving noncisplatin chemotherapy. Semin Oncol 1992;19 (10 Suppl):41S-7S.
22. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur J Cancer 1993;29A: 1669-72.
23. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26(1 Suppl):28S-32S.
24. Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. On Behalf Of The Granisetron Study Group. A double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;8:1083-8.
25. Smith IE. On Behalf Of The Granisetron Study Group. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 1990;26(1 Suppl):19S-23S.
26. Andrews PLR. The pharmacologic profile of granisetron (Kytril). Semin Oncol 1994;21:3-9.
27. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88:497.
28. 3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 1989;159:113-24.
29. Bleiberg HH, Spielmann M, Falkson G, Romain D. Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 1995;17:38-51.
30. Roila F, Tonato M, Basurto C, Canaletti R, Morsia D, Passalacqua R, et al. Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Res 1985;69:1353-7.
31. Roila F, Tonato M, Basurto C, Bella M, Passalacqua R, Morsia D, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone vs metoclopramide alone in cisplatin-treated cancer patients; a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987;5:141-9.
32. Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone vs metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 1989; 7:1693-700.
33. Blijham GH and the Granisetron Study Group. Does granisetron remain effective over multiple cycles? Eur J Cancer 1992;28A (1 Suppl):17S-21S.
34. 3 receptor antagonists. Drugs Future 1989;4:875-89.
35. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982;66:1487-93.
36. Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM. The natural course of emesis after carboplatin treatment. Acta Oncol 1990;29:593-5.
37. Andrews PLR, Blower PP. The physiology of cytotoxic-induced emesis: new insights. Presented at a Satellite to the Seventh European Conference of Clinical Oncology Meeting; 1993 Nov 14-17; Jerusalem (Israel).
38. 4 receptors of the release of 5-hydroxytryptamine from the guinea pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993;347:137-40.
39. Tonato M, Roila F, Del Favero A. Methodology of antiemetic trials: a review. Ann Oncol 1991;2:107-14.
40. Joss RA, Brand BC, Buser KS, Cerny T. The symptomatic control of cytostatic drug-induced emesis. A recent history and review. Eur J Cancer 1990;26(1 Suppl):2S-8S.
41. Diehl V, Marty M. General and supportive care: efficacy and safety of antiemetics. Cancer Treat Rev 1994;20:379-92.
42. Burris H, Hesketh P, Cohn J, et al. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 1996;2:85-90.
43. Heron JF, Goedhals L, Jordaan JP, Cunningham J, Cedar E. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994;5:579-84.